Osimertinib and 6-Thio-dG combination is well tolerated in nude mice, inhibits the growth of osimertinib-resistant tumors, and suppresses EGFR/ERK signaling. (A, B, and F) Treatments were the same as described in Fig. 6. SE, short exposure. (C–E) Treatments were the same as described in Fig. 6 except for the initial tumor sizes, which were over 200 mm³, and osimertinib dosage, which was 15 mg/kg/day. Mice in the vehicle group were sacrificed a few days early before the end of the experiment. The data in each group are means ± SEs of six tumors from six mice. Statistical analysis was conducted with one-way ANOVA test. Source data are available for this figure: SourceData FS4.